These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34525851)

  • 1. Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study.
    Zhao M; Zhang Y; Wang H; Liu P; Da J; Du Y
    Technol Cancer Res Treat; 2021; 20():15330338211038114. PubMed ID: 34525851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
    Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
    Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Wen W; Zhang Y; Zhang H; Chen Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):969-978. PubMed ID: 35771261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
    Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
    BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
    Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
    Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
    Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
    Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
    Tsai HM; Han MZ; Lin YJ; Chang TT; Chen CY; Cheng PN; Chuang CH; Wu IC; Chen PJ; Kang JW; Chiu YC; Chiu HC; Chien SC; Kuo HY
    Cancer Immunol Immunother; 2021 Jul; 70(7):1929-1937. PubMed ID: 33409737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.
    Zheng Z; Mei J; Guan R; Zhang J; Xiong X; Gan J; Li S; Guo R
    Cancer Immunol Immunother; 2024 Jun; 73(8):158. PubMed ID: 38834790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
    Sun T; He J; Zhang S; Sun J; Zeng M; Zeng Z
    Oncotarget; 2016 Jul; 7(30):48586-48599. PubMed ID: 27191894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
    Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
    Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors.
    Zou H; Ge Y; Chen W; Yao D; Oi Lam Ung C; Lai Y; Hu H
    Int Immunopharmacol; 2024 May; 132():111947. PubMed ID: 38552296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study.
    Hsu S; Chao Y; Hu Y; Zhang Y; Hong W; Chen Y; Chen R; Zeng Z; Du S
    Chin Med J (Engl); 2024 Jun; 137(11):1332-1342. PubMed ID: 38725345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
    Song P; Zhang J; Shang C; Zhang L
    Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.